Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
14 nov. 2019 11h02 HE
|
Todos Medical Ltd.
Topline results expected before the end of Q1/2020 REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company...
Todos Medical to Appoint Dr. Paula Trzepacz As Chief Medical Officer And Files New Patent Application
12 juil. 2019 11h05 HE
|
Todos Medical Ltd.
Joint venture Breakthrough Diagnostics files new patent application covering Alzheimer’s blood diagnostic LymPro Test clinical correlation with amyloid PET imagingPreliminary Data on LymPro vs....
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0
08 avr. 2019 07h30 HE
|
Todos Medical Ltd.; Amarantus Bioscience Holdings, Inc.
REHOVOT, Israel and NEW YORK, April 08, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the...
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0
03 déc. 2018 08h30 HE
|
Todos Medical Ltd.
REHOVOT, Israel and NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the...
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
11 déc. 2017 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Allowed claims include the treatment of Type 1 and Type 2 DiabetesOnce issued, patents extend exclusivity for MANF in the US into 2032 SAN FRANCISCO, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Amarantus...
Amarantus BioSciences' CEO Gerald Commissiong to Appear on the Big Biz Radio Show
16 mars 2012 10h13 HE
|
Amarantus BioSciences
SUNNYVALE, Calif., March 16, 2012 (GLOBE NEWSWIRE) -- Amarantus BioSciences, Inc. (OTCBB:AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today...